kojic acid monopalmitate | 79473-00-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: kojic acid monopalmitate
• 英文别名: [6-(hydroxymethyl)-4-oxopyran-3-yl] hexadecanoate
• CAS: 79473-00-0
• 化学式: C₂₂H₃₆O₅
• 分子量: 380.525
• InChiKey: YWNQGJUTMMLRDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  27
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 对甲苯磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 kojic acid monopalmitate
  参考文献：
  名称：

  Bilayer interaction and protein kinase C-C1 domain binding studies of kojic acid esters

  摘要：

  本研究展示了曲酸酯类似物的合成以及它们与脂质双分子层的相互作用和PKC-C1结构域结合特性。

  DOI：

  10.1039/c4ra02352h

文献信息

• AhR mediators
  申请人：Krutmann Jean

  公开号：US20090028804A1

  公开（公告）日：2009-01-29

  The invention relates to a method for finding and assessing agonists [and] antagonists of the aryl hydrocarbon receptor (Ah receptor; AhR), to the agonists and antagonists themselves and to uses thereof.

  这项发明涉及一种用于寻找和评估芳香族羟基化合物受体（Ah受体；AhR）的激动剂和拮抗剂的方法，以及这些激动剂和拮抗剂本身及其用途。
• [EN] A MELANOGENESIS INHIBITOR COMPOSITION<br/>[FR] COMPOSITION INHIBITRICE DE LA MÉLANOGENÈSE
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：WO2019005437A1

  公开（公告）日：2019-01-03

  A melanogenesis inhibitor combination is provided, comprising: a combination of (Z)-N-(4-hydroxybenzylidene)propan-2-amine oxide; and a compound of formula (I) wherein R1 and R2 are independently selected from a hydrogen atom and an acyl group having 3 to 20 carbon atoms; wherein the combination is dispersed in a dermatologically acceptable carrier.

  提供一种黑色素生成抑制剂组合物，包括：（Z）-N-（4-羟基苄基）丙烯醛胺氧化物的组合物；以及式（I）中的化合物，其中R1和R2分别选自氢原子和具有3到20个碳原子的酰基团；其中该组合物分散在皮肤学上可接受的载体中。
• Kinetics and Optimization of Lipophilic Kojic Acid Derivative Synthesis in Polar Aprotic Solvent Using Lipozyme RMIM and Its Rheological Study
  作者：Nurazwa Ishak、Ahmad Lajis、Rosfarizan Mohamad、Arbakariya Ariff、Mohd Mohamed、Murni Halim、Helmi Wasoh

  DOI：10.3390/molecules23020501

  日期：——

  RMIM, was derived from the lipase of Rhizomucor miehei immobilized on weak anion exchange macro-porous Duolite ES 562 by the adsorption technique. The effects of solvents, enzyme loading, reaction temperature, and substrate molar ratio on the reaction rate were investigated. In one-factor-at-a-time (OFAT) experiments, a high reaction rate (30.6 × 10-3 M·min-1) of KAD synthesis was recorded using acetone

  使用摇瓶系统研究了在固氮脂酶（商品名为Lipozyme RMIM）固定化脂肪酶存在下，由曲酸和棕榈酸（C16：0）合成曲酸衍生物（KAD）的方法。曲酸是一种多官能团的杂环，它在此反应中充当亲核试剂的来源，从而形成亲脂性KAD。在这项研究中，生物催化剂脂酶RMIM的来源是通过吸附技术将米糠根瘤菌的脂肪酶固定在弱阴离子交换大孔Duolite ES 562上。研究了溶剂，酶载量，反应温度和底物摩尔比对反应速率的影响。在一次单因素（OFAT）实验中，使用丙酮记录了KAD合成的高反应速率（30.6×10-3 M·min-1），酶载量为1.25％（w / v），反应时间为12小时，温度为50°C，底物摩尔比为5：1。此后，通过响应表面方法（RSM）对KAD合成的收率进行了优化，其中优化的摩尔比（脂肪酸：曲酸），酶负载，反应温度和反应时间分别为6.74、1.97％（w / v），45.9分别在20°C和20°C时，KAD的收率高（64
• EXTRACT POWDER OF INDIGO PLANT, AND ITS PREPARATION AND USES
  申请人：Fujii Mitsukiyo

  公开号：US20100034757A1

  公开（公告）日：2010-02-11

  The present invention has objects to provide an extract powder of indigo plant, which has a relatively low hygroscopicity, satisfactory fluidability, and improved storage stability; a process thereof; and a composition incorporated with the extract powder. The objects are solved by a process for producing an extract powder of indigo plant, which comprises incorporating a partial starch hydrolyzate with a dextrose equivalent of 10.2 or lower into one part by weight, on a dry solid basis, of an indigo plant extract contained in a liquid extract of indigo plant in an amount of not lower than 0.25 part by weight but not higher than 5 parts by weight, on a dry solid basis, and drying the resulting mixture; an extract powder of indigo plant prepared thereby; and a composition incorporated with the extract powder.

  本发明旨在提供一种靛蓝植物的提取粉末，其具有相对较低的吸湿性、满意的流动性和改善的储存稳定性；其制备方法；以及与提取粉末混合的组合物。通过将DE值为10.2或更低的部分淀粉水解物以不低于0.25份重量但不高于5份重量的干固物基础加入到液态提取的靛蓝植物提取物的一份重量中，并将所得混合物干燥，来解决上述问题；由此制备的靛蓝植物提取粉末；以及与提取粉末混合的组合物。
• TOPICAL AGENT FOR DERMATOLOGICAL USE
  申请人：Nakayama Hiroki

  公开号：US20110014141A1

  公开（公告）日：2011-01-20

  The objective of the present invention was to enhance the skin whitening effects and blackening prevention effects and supply safe and stable topical agents for dermatological use. For that purpose 4-Hydroxyphenyl-α-D-glucopyranoside was combined with auxiliary agents such as ascorbic acid and its derivatives, crude drugs and its extracts, hydroxycarboxylic acid and its salts, oil soluble glycyrrhiza extract, gentian extract, phenol derivatives and their salts, placenta extract, kojic acid and its derivatives, glucosamine and its derivatives, azelaic acid and its derivatives, retinol and its derivatives, pyridoxin and its derivatives, tocopherol and its derivatives, chitosan and its decomposition products, caffeic acid derivatives, hydroxycinnamate and its derivatives, Umbelliferae plant extracts, mycelial cultures and their extracts, plant leaves and their extracts.

  本发明的目的是增强皮肤美白效果和黑色素生成的预防效果，并提供安全稳定的用于皮肤科的局部制剂。为此，4-羟基苯基-α-D-葡萄糖苷与辅助剂如抗坏血酸及其衍生物、天然药物及其提取物、羟基羧酸及其盐、油溶性甘草提取物、龙胆提取物、酚类衍生物及其盐、胎盘提取物、曲酸及其衍生物、葡萄糖胺及其衍生物、癸二酸及其衍生物、视黄醇及其衍生物、吡哆醇及其衍生物、生育酚及其衍生物、壳聚糖及其分解产物、咖啡酸衍生物、羟基肉桂酸及其衍生物、伞形科植物提取物、菌丝培养物及其提取物、植物叶片及其提取物相结合。